Halia Therapeutics Initiates Phase II Clinical Trial to Eval

Halia Therapeutics Initiates Phase II Clinical Trial to Evaluate Efficacy of HT-6184, a First-in-Class NEK7/NLRP3 Inhibitor, on Post Procedural Inflammatory and Pain Responses

Halia Therapeutics Initiates Phase II Clinical Trial to Evaluate Efficacy of HT-6184, a First-in-Class NEK7/NLRP3 Inhibitor, on Post Procedural Inflammatory and Pain Responses

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

The Post , Utah , United States , Salt Lake City , Dave Bearss , Margitm Jan , Ignacio Guerrero Ros , Russo Partners , Company Contact , Halia Therapeutics Inc , Halia Therapeutics , Chief Medical Officer , Chief Executive Officer , Reduce Inflammation , Lake City , Post Procedural Inflammatory ,